Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome
Kiel MJ, Sahasrabuddhe AA, Rolland DC, Velusamy T, Chung F, Schaller M, Bailey NG, Betz BL, Miranda RN, Porcu P, Byrd JC, Jeffrey Medeiros L, Kunkel SL, Bahler DW, Lim MS, Elenitoba-Johnson KS. Nat Commun. 2015 Sep 29;6:8470. doi: 10.1038/ncomms9470.
Summary
Sezary syndrome (SS), an aggressive leukemia of mature T cells, is more complicated at a molecular level than ever suspected, according to research published by the Elenitoba-Johnson Lab in Nature Communications. With a poor prognosis and limited options for targeted therapies, fighting SS needs new treatment approaches. The team’s results uncover a previously unknown, complex genomic landscape of this cancer, which can be used to design new personalized drug regimens for SS patients based on their unique genetic makeup.
Read the Department of Communications news release.
